Li Kang Biomedical Co Ltd (6242) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Li Kang Biomedical Co Ltd TWD 25.19, price TWD 34.10, upside -26.1%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Li Kang Biomedical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014.
Show more
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
Stock analysis
Li Kang Biomedical Co Ltd (6242) currently trades at 34.10 TWD, while our model-based Fair Value estimate is 25.19 TWD, implying the stock looks roughly 35.4% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 44.80 TWD per share, and 5 of the 14 models we run sit above the 34.10 TWD price.
Bear case: the Asset-Based group reads lowest at 18.35 TWD, and 9 of the 14 models stay below the price. Evidence for this calculation is high.
Scenario range: 23.15 TWD (bear) to 29.97 TWD (bull), the price of 34.10 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Consumer Cyclical sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Li Kang Biomedical Co Ltd reported revenue of 589M TWD in FY2025 versus 387M TWD in FY2021, a compound +11.1%/yr. Reported net income was 83.8M TWD in FY2025, compounding +13.0%/yr from FY2021.
Key figures
Market cap 1.1B TWD (≈ $34.1M) · P/E ratio 13.0 · P/S ratio 1.85 · EPS (TTM) 2.62 TWD · Dividend yield 5.9% · Net margin 14.2% · Return on equity 8.9% · Return on assets (EBIT) 13.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 10% fair-value upside, at −26%, 6242 screens richer than that median.
Fair Value models
Bear 23.15 TWDFair Value 25.19 TWDBull 29.97 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.4552 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Start year 2020 (pandemic). Over 10 years: +2.6% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.2%
Dividend (yield on the price)5.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 17%
⚠ Revenue per share shrinking 3.1%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Li Kang Biomedical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Travel Services · 88 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−26% · Below median
Profitability
Return on equity (TTM)9% · Above median
Return on assets5% · Above median
Net margin (TTM)13% · Top 25%
Operating margin (TTM)11% · Above median
Growth and dividend
Revenue growth−10% · Bottom 25%
Dividend yield (TTM)5.9% · Top 25%
Valuation Multiplesvs Travel Services median · lower = cheaper
P/E (TTM)13.0× · Cheaper than median
P/B1.24× · Cheaper than median
P/S (TTM)1.88× · Pricier than median
EV/EBITDA10.5× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 49
FUTURE (revenue growth)0· sector 25
PAST (return on equity)35· sector 35
HEALTH (low debt)100· sector 94
DIVIDEND (yield)100· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Li Kang Biomedical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6242
Frequently asked questions
Is Li Kang Biomedical Co Ltd (6242) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 25.19 TWD versus a price of 34.10 TWD, about −26% upside (overvalued).
What is the fair value of 6242?
Our model-based fair value for Li Kang Biomedical Co Ltd is 25.19 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 34.10 TWD.
What is the quality score of 6242?
Li Kang Biomedical Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Li Kang Biomedical Co Ltd (6242)?
Our model-based price target is the fair value of 25.19 TWD (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 23.15 TWD, optimistic scenario 29.97 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Li Kang Biomedical Co Ltd stock forecast for 2026?
Our models put fair value at 25.19 TWD, about −26% upside versus a price of 34.10 TWD (overvalued). Cautious scenario 23.15 TWD, optimistic scenario 29.97 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Li Kang Biomedical Co Ltd (6242)?
Li Kang Biomedical Co Ltd reported trailing-twelve-month revenue of about 576M TWD (latest available figure, as of Sep 24, 2026).
Does Li Kang Biomedical Co Ltd pay a dividend?
Li Kang Biomedical Co Ltd currently shows a dividend yield of about 5.87% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Li Kang Biomedical Co Ltd (6242)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Li Kang Biomedical Co Ltd it is 25.19 TWD per share (as of Sep 24, 2026), against a price of 34.10 TWD. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Li Kang Biomedical Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6242 trades above its calculated fair value: price 34.10 TWD, fair value 25.19 TWD, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6242?
No. The price is what the market pays today (34.10 TWD); the fair value is what the company's own numbers justify (25.19 TWD). For Li Kang Biomedical Co Ltd the two are 8.91 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Li Kang Biomedical Co Ltd worth?
The market values Li Kang Biomedical Co Ltd at about 1.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 34.10 TWD; our models calculate a fair value of 25.19 TWD per share.
What do the bullish and bearish scenarios say about 6242?
Our models span a range for Li Kang Biomedical Co Ltd: cautious scenario 23.15 TWD, base 25.19 TWD, optimistic 29.97 TWD per share (as of Sep 24, 2026, price 34.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6242?
Li Kang Biomedical Co Ltd trades at a price-to-earnings ratio of 13.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 25.19 TWD is built from several models across several years. Other multiples: P/B 1.2, P/S 1.9, EV/EBITDA 10.5.
How solid is the balance sheet of Li Kang Biomedical Co Ltd (6242)?
Balance-sheet figures for Li Kang Biomedical Co Ltd (as of Sep 24, 2026): return on equity 8.9%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 6242 from its 52-week high?
Li Kang Biomedical Co Ltd trades at 34.10 TWD, about 13% below its 52-week high of 39.13 TWD and 1% above the low of 33.60 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 25.19 TWD is for.
Which stocks are comparable to Li Kang Biomedical Co Ltd?
From the same area (Consumer Cyclical) we also value Booking Holdings, Airbnb, Inc, Royal Caribbean Cruises Ltd, Viking Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Li Kang Biomedical Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 34.10 TWD, calculated fair value 25.19 TWD (−26%), Quality Score 45/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6242 calculated?
We run Li Kang Biomedical Co Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 25.19 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Li Kang Biomedical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Li Kang Biomedical Co Ltd (6242)?
The closing price on Sep 24, 2026 was 34.10 TWD. Our model-based fair value is 25.19 TWD, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Li Kang Biomedical Co Ltd right now?
The price sits above even our optimistic bull case (29.97 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Li Kang Biomedical Co Ltd
How large is the market capitalisation of Li Kang Biomedical Co Ltd (6242)?
The market capitalisation of Li Kang Biomedical Co Ltd is 1.1B TWD (≈ $34.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Li Kang Biomedical Co Ltd (6242)?
The price-to-sales ratio of Li Kang Biomedical Co Ltd is 1.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Li Kang Biomedical Co Ltd (6242)?
Earnings per share at Li Kang Biomedical Co Ltd are 2.62 TWD (price ÷ EPS = P/E 13.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Li Kang Biomedical Co Ltd (6242)?
The dividend yield of Li Kang Biomedical Co Ltd is 5.9% (payout 76.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Li Kang Biomedical Co Ltd (6242)?
The net margin of Li Kang Biomedical Co Ltd is 14.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Li Kang Biomedical Co Ltd (6242)?
The return on equity (ROE) of Li Kang Biomedical Co Ltd is 8.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Li Kang Biomedical Co Ltd (6242)?
On an EBIT basis the return on assets of Li Kang Biomedical Co Ltd is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Li Kang Biomedical Co Ltd (6242)?
The operating margin of Li Kang Biomedical Co Ltd is 10.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Li Kang Biomedical Co Ltd (6242)?
Revenue at Li Kang Biomedical Co Ltd is growing −9.8% versus a year earlier (3y avg −4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Li Kang Biomedical Co Ltd (6242)?
Earnings per share at Li Kang Biomedical Co Ltd are growing −37.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Li Kang Biomedical Co Ltd (6242) generate?
The free cash flow of Li Kang Biomedical Co Ltd is −237M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Li Kang Biomedical Co Ltd (6242) carry?
The net debt of Li Kang Biomedical Co Ltd is 49.4M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Li Kang Biomedical Co Ltd in the live analysis
One click puts Li Kang Biomedical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
